“GLP-1 weight-loss drugs cause muscle loss.”
GLP-1 drugs do not cause unusual muscle loss: some lean tissue comes off along with fat, in about the same share as with diet-based weight loss.
Losing some lean tissue is a normal part of losing a lot of weight, with or without a GLP-1 drug, and it is not a reason to stop a prescribed medicine. Lifting weights and eating enough protein are the best-supported ways to keep more muscle while the weight comes off, as covered in our card "Lifting weights while losing weight protects your muscle."
If you take a GLP-1 drug, add two or three strength sessions a week and ask your care team to track your strength along with your weight.
Safety note: Older or frail adults, and people who already have low muscle or are eating very little, have the least muscle to spare, so strength and function checks, enough protein and strength training matter most for them during GLP-1 treatment.
Talk to a healthcare professional if: you are taking a GLP-1 drug and are older or frail, feel weaker, have fallen, or are struggling to eat enough.
A 20-trial meta-analysis found that the share of weight lost as lean mass on GLP-1 drugs is about the same as on lifestyle programs, and reviews find strength and function generally hold up. Body scans measure lean mass rather than muscle alone and long-term data are limited, which is why confidence is Moderate.
GLP-1 drugs do not cause unusual muscle loss: some lean tissue comes off along with fat, in about the same share as with diet-based weight loss. Across 20 trials, lean mass made up about 25 to 35 percent of the weight lost on GLP-1 and related drugs, compared with about 26 percent on lifestyle programs and about 18 percent when those programs added lifting. Most of the weight lost is fat, lean mass includes water and organs as well as muscle, and studies have not shown a consistent loss of strength or everyday function.
In the 20-trial analysis, the lean share was about 35 percent with semaglutide, 25 percent with tirzepatide and 27 percent with liraglutide, and the drug and lifestyle shares did not differ clearly overall. A review of randomized and controlled studies found GLP-1 drugs take off more fat than lean mass and that strength and function generally hold up. Professional nutrition groups advise resistance training, enough protein and checks of strength and body composition during treatment, especially for higher-risk patients.
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(6):4818-4827. DOI: 10.1111/dom.70666. PMID: 41877354
- De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin-based therapies. European Journal of Clinical Investigation. 2026;56(1):e70155. DOI: 10.1111/eci.70155. PMID: 41328795. PMCID: PMC12825403
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. DOI: 10.1002/oby.24336. PMID: 40445127. PMCID: PMC12304835